What Estromil Treats: Main Uses and Benefits

This medication is primarily relevant for easing symptoms in veterinary reproductive medicine, applied across domains where additional symptomatic support is needed to support stability in the ovarian cycle. It is commonly used for managing unpredictable reproductive timing and in conditions characterized by periods of heightened physiological stress related to uterine and ovarian pathology.

The main therapeutic uses involve assisting with the management of pyometra, chronic endometritis, and ovarian luteal cysts, as well as the synchronization or induction of estrus and the resolution of suboestrus (silent heat). This supportive relief helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability in breeding animals.

Quick Fact: Relief for Irregular Reproductive Timing

This medication is commonly used when short-term symptomatic assistance is needed to achieve precise timing of estrus and manage conditions like suboestrus.

Regulatory References

1. United States FDA regulations on Cloprostenol

Eligibility Map: Who Can and Cannot Use Estromil — Official Regulatory Information

Eligibility Scope

• Populations for whom use is allowed (as stated in label): Cattle, specifically beef cows, lactating dairy cows, and replacement heifers. Use is also permitted in mares and, in some regions, in sows and gilts.

• Populations for whom use is contraindicated: Administration is strictly prohibited in pregnant animals unless the explicit goal is to terminate the pregnancy or induce parturition. The medicine is also contraindicated in animals with existing compromised cardiovascular function, bronchospasm, or gastrointestinal dysmotility.

• Condition-specific eligibility rules: Use is contingent on the animal possessing a functional corpus luteum in the ovary. The drug must not be used to induce parturition in animals with suspected obstructive dystocia.

• Pregnancy and lactation eligibility status: Use during pregnancy is conditionally permitted only for abortion (up to specific gestation limits) or induction. The medicine is permitted for use in lactating dairy cows.

Eligibility classifications (high-level)

• Eligibility severity classification: Contraindication is formally applied to certain pregnant groups and those with pre-existing organ dysfunction. Use is considered restricted or conditional when the animal is in a non-responsive period (refractory period) or when inducing specific procedures.

Resulting eligibility structure

• Administration is permitted in cows, heifers, and mares that meet the physiological requirement of possessing a functional corpus luteum.
• The medicine is formally contraindicated in animals with compromised cardiovascular, respiratory, or gastrointestinal function.
• It must not be used in pregnant animals unless the specific use is for the induction of abortion or parturition.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing three primary criteria: the animal must be a target species with a functional corpus luteum; it must be free of specific comorbidities involving the cardiovascular, respiratory, or gastrointestinal systems; and if pregnant, the use must be for termination, not maintenance of the pregnancy.

Official Interaction Profile

The regulatory profile for Cloprostenol sodium (Estromil) is defined primarily by pharmacodynamic interactions and administration sequencing requirements. No interactions mediated by Cytochrome P450 (CYP) enzymes or drug transporters are explicitly documented in official regulatory sources.

Contraindicated Combinations

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is formally contraindicated according to official regulatory labels. The restriction stems from the NSAIDs' documented ability to inhibit the synthesis of natural prostaglandins, an action that directly opposes the therapeutic effect of the synthetic prostaglandin analogue.

Documented Pharmacodynamic Effects

Interacting Product Category	Official Effect Description
Oxytocin	Documented pharmacodynamic synergism, resulting in an increased effect on the uterus.
Progestogens	Officially stated to decrease the therapeutic response to Cloprostenol.

Administration Timing Constraint

When utilized within a fixed-time synchronization program, the administration of Estromil must adhere to a specific timing-based interaction rule. Official protocols require the product to be administered in a controlled sequence, specifically 6 to 8 days following an initial injection of Gonadorelin (GnRH), as defined in FDA regulatory standards.

No interactions with food, alcohol, herbal products, or supplements are documented in the official prescribing information.

Estromil, whose active pharmaceutical ingredient is cloprostenol sodium, functions as a synthetic structural analog of prostaglandin F2alpha ( PGF2alpha). The molecule acts as an agonist at the Prostaglandin F2alpha receptor (FP receptor), which is a G-protein coupled receptor. Upon binding, cloprostenol initiates a downstream intracellular cascade primarily targeting the corpus luteum (CL) tissue in the ovary.

Activation of the FP receptor on luteal cells induces functional and structural regression of the corpus luteum, a process termed luteolysis. This cellular process involves an inhibition of luteal steroidogenesis and subsequent reduction in the systemic concentration of the steroid hormone progesterone. The systemic consequence of decreased circulating progesterone is the elimination of its negative feedback on the hypothalamic-pituitary-ovarian axis, which thereby modulates the reproductive cycle and permits a subsequent follicular phase and ovulation.

How to Use Estromil (Cloprostenol Injection)

The administration of Estromil, a veterinary product containing Cloprostenol sodium, follows specific instructions to ensure proper usage of the injectable solution.

Official Administration and Dosing

Guideline	Instruction
Route of Administration	Exclusively INTRAMUSCULAR INJECTION (IM).
Standard Cattle Dose	2 mL (equivalent to 500 micrograms (mu g) Cloprostenol).
Horse Dosing Range	Varies by size, typically 0.5 mL to 2.0 mL (125 micrograms (mu g) to 500 micrograms (mu g)).
Synchronization Schedule	Requires a second 2 mL injection exactly 11 days after the first dose.

Required Procedural Steps

Administration must strictly utilize aseptic techniques, requiring thorough cleaning and disinfection of the injection site before application. Proper preparation involves ensuring the sterility of all equipment used for the injection. The medicine is supplied as a ready-to-use solution and requires no dilution or reconstitution prior to use.

Container Handling and Time-Bound Use

Multi-dose vials, such as the 100 mL format, must be used only with automatic injection equipment or a repeater syringe. Furthermore, once the vial's seal is punctured for the first time, the medicine must be discarded if not used within the specified period, typically 28 days, to maintain product integrity and sterility. Dosage instructions may also specify use based on the animal's weight or maturity, such as the requirement for use in pigs to be not earlier than 114 days of pregnancy.

Research Evidence / Overview of Studies for Estromil

This section provides a factual overview of the types of research and clinical studies that have been conducted on the active ingredient, Cloprostenol sodium, to support its regulatory approval. The summaries focus on the structure of the evidence, the outcomes that were measured, and identified gaps, remaining strictly non-advisory.

---

Evidence for Use in Estrus Synchronization and Controlled Breeding

Research exploring how the timing of the reproductive cycle was studied primarily utilized Randomized Controlled Trials (RCTs) and various comparative field studies. Studies monitored outcomes such as the precise time interval from administration to the animal exhibiting visible heat (estrus) or ovulation, as well as longer-term outcomes related to subsequent conception and pregnancy rates.

The findings describe patterns observed in the studies where measurements related to the timing of reproductive events were monitored within a defined period following administration. Research highlights changes measured during the study period, noting that a percentage of animals displayed synchronized reproductive events across different management protocols. However, the certainty of findings remains low for a universal protocol, as results often varied across studies, which can be linked to differences in protocol design.

Evidence for Therapeutic Management of Uterine and Ovarian Conditions

The evidence for using the medicine in conditions characterized by functional imbalance, such as Pyometra, Chronic Endometritis, and Ovarian Luteal Cysts, is largely derived from observational studies, field trials, and case series. Research examined outcomes related to the resolution of the persistent ovarian structure known as the Corpus Luteum (CL), and clinical assessments of changes related to the uterine disease.

Studies reported how symptoms evolved in the observed populations, describing the physical clearance of discharge and signs of changes in reproductive cyclicity following administration. A key limitation here is that the medicine was frequently used in combination with other supportive treatments, such as antibiotics, in many of the studies. This makes it difficult to isolate the contribution of Estromil alone to the overall clinical outcome, meaning the evidence quality varies across studies.

What is Still Uncertain About Estromil Research

The research on Estromil contributes to the broader evidence landscape, but several areas remain uncertain. The independent effect of the medicine is often unclear when it is used as part of a combination therapy. Additionally, the comparative evidence between Estromil and other drugs in its class, or different protocols for its use, is often lacking in systematic, head-to-head trials. Overall, the data show patterns related to the targeted reproductive endpoints, but the results apply only to the populations studied and do not determine whether an individual animal will respond similarly.

Key Studies & References

1. United States FDA Regulations on Cloprostenol (21 CFR § 522.460) - Therapeutic Uses and Indications
2. NIH DailyMed: Cloprostenol Sodium Injection (Veterinary) - Composition and Pharmacological Information

Common questions about Estromil (FAQ)

Q: Is Estromil available in different forms, such as a pill or a patch?

No. Official documentation states that Estromil is only supplied as a sterile aqueous solution intended for intramuscular injection. Regulatory labels do not describe or authorize its use in any other forms, such as a pill, patch, or topical application.

Q: Is there a link between using Estromil and an increased risk of blood clots?

Official regulatory sources do not explicitly list blood clots, DVT, or thrombosis as documented adverse reactions in the target animal species. The safety profile notes transient cardiovascular effects, such as an increased heart rate (tachycardia), and contraindicates use in animals with pre-existing compromised cardiovascular function.

Q: Does Estromil cause patients to gain weight?

Official regulatory documents do not list weight gain as a documented adverse reaction or expected side effect in the target animal populations. The documented effects are typically transient smooth muscle reactions, such as abdominal discomfort, sweating, and increased respiratory rate.

Q: What happens to symptoms if a patient stops taking Estromil?

When administration is discontinued, the intended luteolytic effect—the intentional breakdown of the corpus luteum—is no longer sustained. The reproductive cycle is then described as returning to its natural course. For synchronized use, the label notes that estrus (heat) typically occurs 2 to 5 days after the last injection.

Q: Is Estromil typically used by women over the age of 60?

Estromil is strictly a prescription-only veterinary medicine authorized for use only in specific target animal species, such as cattle, horses, and pigs. It is not licensed, labeled, or intended for human use; therefore, human age or gender is irrelevant to its official regulatory purpose.

Q: What are the official safety warnings associated with Estromil?

Official warnings include the risk of severe localized clostridial infections at the injection site and the potential for a very rare, serious allergic reaction called anaphylaxis. Additionally, user safety warnings indicate the product is readily absorbed through the skin and carries the potential risk of causing abortion or bronchospasms in handlers, especially women of childbearing age, asthmatics, and those with respiratory issues.

Q: What is a known side effect on mood or anxiety levels with Estromil?

Official documentation and adverse event classifications do not list effects on mood, anxiety, or psychological state as documented adverse reactions in the target animal species.

Q: Can Estromil cause headaches or nausea?

The safety profile documents transient systemic effects such as abdominal discomfort or colic. Headache and nausea are not explicitly listed as documented adverse effects on the official regulatory labels for the target species.

Q: Are there any rare but serious side effects associated with Estromil?

Yes, regulatory documents describe the risk of severe localized clostridial infections at the injection site, which is considered life-threatening. Anaphylaxis is also documented as a very rare but serious systemic adverse reaction.

Q: What types of research evidence are available for Estromil's use?

Research evidence includes Randomized Controlled Trials (RCTs) and field studies focusing on reproductive synchronization. Observational studies and case series support its use for reproductive conditions like Pyometra and Luteal Cysts. The evidence quality varies, particularly where the medicine was used alongside other supportive treatments.

Q: What is meant by the 'window of opportunity' in relation to starting Estromil?

This term refers to the timing required for the medicine to be effective. The drug works solely by causing the breakdown of the corpus luteum (luteolysis), which is only present during a specific phase of the reproductive cycle. Therefore, for the medicine to achieve its intended effect, administration is conditioned on the presence of the active corpus luteum during this specific window.

Q: What is the difference between systemic and local Estromil treatment?

Official documents describe Estromil only as a sterile aqueous solution intended for a systemic route of administration via intramuscular injection. This means the medicine is intended to enter the general circulation. A local (e.g., intrauterine) route is not described in the official regulatory profile.

How to Store and Dispose of Estromil?

The storage and handling of Estromil (Cloprostenol sodium injection) must strictly follow official regulatory guidelines to maintain its stability.

Storage Requirements

The medicine requires storage at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F). It must be protected from both freezing and light exposure and should be kept in its original outer carton under dry conditions. The product must be stored out of the sight and reach of children.

Stability and Disposal

The stability of the product after the vial is first opened is defined by the specific label and may be 28 days or 180 days; this authorized in-use period must be observed. Disposal of unused medicine, residues, and used needles must follow specific national and local regulations for pharmaceutical waste and sharps. Sharps (syringes and needles) must be placed immediately in an approved container, and the product must not be disposed of in household trash or wastewater.